Xilio Therapeutics, Inc. Income Statement
XLO|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Xilio Therapeutics, Inc. reported $6M in revenue and $58M in net loss for FY2025. Revenue increased 0.0% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.71 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6.3M | $6.3M |
| SG&A Expense | $24.8M | $27.0M |
| R&D Expense | $41.2M | $52.1M |
| Operating Income | -$60.6M | -$79.1M |
| Income Tax | $0 | $0 |
| Net Income | -$58.2M | -$76.4M |
| EPS (Basic) | -$15.24 | -$2.78 |
| EPS (Diluted) | -$15.24 | -$2.78 |
| Shares Outstanding | 3.3M | 27.6M |
| Operating Margin | -955.0% | -1247.4% |
| Profit Margin | -918.1% | -1204.3% |